EcoDrugPlus

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSOCUG00000017891
Gene Symbol: SLC29A1
3 Cross references
284 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSOCUG00000017569
Gene Symbol: SLC5A1
3 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSOCUG00000021091
Gene Symbol: SLC5A2
3 Cross references
197 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSOCUG00000017310
Gene Symbol: SLC6A2
3 Cross references
202 Possible Orthologues:

Solute Carrier Family 6 Member 4

Ensembl ID : ENSOCUG00000003640
Gene Symbol: SLC6A4
3 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSOCUG00000023733
Gene Symbol: SLC6A9
2 Cross references
208 Possible Orthologues:

Solute Carrier Family 9 Member A3

Ensembl ID : ENSOCUG00000011055
Gene Symbol: SLC9A3
2 Cross references
234 Possible Orthologues:

Somatostatin Receptor 1

Ensembl ID : ENSOCUG00000008670
Gene Symbol: SSTR1
3 Cross references
158 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSOCUG00000009347
Gene Symbol: SSTR2
2 Cross references
263 Possible Orthologues:

Somatostatin Receptor 3

Ensembl ID : ENSOCUG00000026665
Gene Symbol: SSTR3
2 Cross references
249 Possible Orthologues:

Sphingosine-1-Phosphate Receptor 1

Ensembl ID : ENSOCUG00000015574
Gene Symbol: S1PR1
3 Cross references
200 Possible Orthologues:

Spleen Associated Tyrosine Kinase

Ensembl ID : ENSOCUG00000017539
Gene Symbol: SYK
2 Cross references
200 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).